NEWS DETAIL

Telix Seneffe Production Facility: Progress Update

Melbourne (Australia) and Seneffe (Belgium) – 30 July 2021. Telix Pharmaceuticals Limited (ASX: TLX, ‘Telix’, the ‘Company’) today announces that it has received authorisation from the Belgian Agence Fédérale de Contrôle Nucléaire (AFCN) to decommission the first of two cyclotrons housed at the Company’s licensed radiopharmaceutical production facility in Seneffe, Belgium. The authorisation means that the AFCN has accepted Telix’s decommissioning dossier, submitted with the support of SCK-CEN (the Belgian Nuclear Research Centre), and is satisfied that safety and operational requirements will be met.

Telix Seneffe General Manager, Sébastien Linard stated, “This authorisation represents a significant milestone for Telix as it enables the build-out of a state-of-the art radiopharmaceutical production facility that will ultimately serve as Telix's primary EU manufacturing site. This outcome is also positive for the Wallonia region as Telix's production footprint will create local employment and partnership opportunities, further contributing to Belgium's impressive radiopharmaceutical ecosystem. We would like to thank our collaborator SCK-CEN and our radioprotection advisor Be.Sure ASBL for their support in developing the dossier for AFCN submission.”

About Telix’s Seneffe (Belgium) Facility 

Telix’s nuclear facility in Seneffe, Belgium, was acquired in April 20201 , allowing the Company to set up a broad radiopharmaceutical production facility with significant operational flexibility. This vertically integrated approach to radioisotope and finished radiopharmaceutical production has the ability to meet the Company’s commercial production needs for its entire product portfolio in Europe, both increasing Telix’s independence and reducing exposure to interruptions in radioisotope supply.

About Telix Pharmaceuticals Limited

Telix is a biopharmaceutical company focused on the development of diagnostic and therapeutic products using Molecularly Targeted Radiation (MTR). Telix is headquartered in Melbourne, Australia with international operations in Belgium, Japan, and the United States. Telix is developing a portfolio of clinical-stage products that address significant unmet medical need in oncology and rare diseases. Telix is listed on the Australian Securities Exchange (ASX: TLX). For more information visit www.telixpharma.com and follow Telix on Twitter (@TelixPharma) and LinkedIn.

Telix’s lead investigational product, Illuccix® (TLX591-CDx) for prostate cancer imaging, has been accepted for filing by the U.S. FDA,2 and is under priority evaluation by the Australian Therapeutic Goods Administration (TGA).3 Telix is also progressing marketing authorisation applications for Illuccix® in the European Union4 and Canada.5 None of Telix’s products have received a marketing authorisation in any jurisdiction.

Telix Investor Relations

Ms. Kyahn Williamson
Telix Pharmaceuticals Limited
SVP Corporate Communications and Investor Relations
Email: [email protected]

Important Information 

This announcement does not constitute an offer to sell, or a solicitation of an offer to buy, securities in the United States, or in any other jurisdiction in which such an offer would be illegal. The securities referred to herein have not been and will not be registered under the United States Securities Act of 1933 (the “U.S. Securities Act”), or under the securities laws of any state or other jurisdiction of the United States and may not be offered or sold within the United States, unless the securities have been registered under the U.S. Securities Act or an exemption from the registration requirements of the U.S. Securities Act is available. None of the technologies or products described in this document have received a marketing authorisation in any jurisdiction. This announcement has been authorised for release by Dr Christian Behrenbruch, Managing Director and Chief Executive Officer.

_______________
1 ASX disclosure 3/05/20.
2 ASX disclosure 24/11/20.
ASX disclosure 14/04/21.
4 ASX disclosure 1/05/20.
5 ASX disclosure 16/12/20.